Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone in 3rd-line+ SCLC
NCT05299255Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2021
- Primary completion
- Sep 2022
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone in small cell lung cancer (SCLC), sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
utidelone
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05299255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05299255.